Uncategorized
Earlier therapy reduces need for surgery in JIA-related uveitis
NASHVILLE, Tenn. — The sooner a patient with juvenile idiopathic arthritis-related and idiopathic uveitis receives both methotrexate and a second immunomodulatory therapy agent, the sooner the patient will experience better control over the uveitis, according to a study.“Earlier initiation of both methotrexate and a second IMT [immunomodulatory] agent, if required, is associated with a reduced likelihood of needing any ophthalmic surgeries at 3 years. [Patients] are less likely to need more than three times a day of topical prednisolone, and [there is] overall improved uveitis control,” Crystal S. Cheung, MD, (Read more...)